Trophoblastic disease: twenty years' experience at Niigata University.
The author engaged in the registration work and the clinical studies of trophoblastic disease over 20 years at Niigata University in Niigata prefecture, before transferring to University of the Ryukyus in Okinawa prefecture in 1992. In this paper, the following four topics are reviewed and discussed. 1) the registration data of trophoblastic disease in Niigata prefecture, 2) the treatment results of gestational chorio-carcinoma at the Niigata University Hospital, 3) a trial administration of Gn-RH analogue in patients with gestational choriocarcinoma to suppress secretion of hCG-like substance (hLS) which might cross-react anti-hCG antibodies in hCG immunoassay system, 4) the two rare cases of extrauterine gestational choriocarcinoma who were presented to the Ryukyus University Hospital.
Kanazawa
K
K
University of the Ryukyus, Faculty of Medicine, Department of Obstetrics and Gynecology, Okinawa, Japan.
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002064:Buserelin / Q000627:therapeutic use; D002822:Choriocarcinoma / Q000188:drug therapy; D005260:Female; D006801:Humans; D007564:Japan; D011247:Pregnancy; D011379:Prognosis; D012189:Retrospective Studies; D014328:Trophoblastic Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy
D018931:Antineoplastic Agents, Hormonal; D002064:Buserelin